Dr Akash Kalro

MBBS, MD, FRCPA, FRACP
Clinical Haematologist
Make an Appointment

Dr Akash Kalro is dedicated to delivering the highest level of care to his patients. He brings a compassionate, measured approach to his practice to ensure his patients are supported throughout their treatment and beyond.

Biography

Dr Akash Kalro is an experienced clinical haematologist at Icon Cancer Centre Adelaide and Icon Cancer Centre Windsor Gardens. In 2003, he completed his Bachelor of Medicine and Bachelor of Surgery (MBBS) and Doctor of Medicine (MD) at the University of Mumbai before commencing specialist haematology training at Sydney’s Nepean Hospital and Westmead Hospital. Prior to relocating to Adelaide, Dr Kalro held a prominent role as a clinical haematologist at Royal Darwin Hospital where he established the Northern Territory’s first flow cytometry service and was director of their haemophilia treatment centre.

Dr Kalro holds a strong interest in clinical research, trials and education, actively participating in haematology clinical trials as principal and sub-investigator. In addition to his practice at Icon, Dr Kalro also treats patients at The Queen Elizabeth Hospital and Royal Adelaide Hospital and is an on-site haematologist at Australian Clinical Labs. He is a fellow of the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA).

Dr Kalro is experienced in caring for a wide range of malignant and non-malignant blood disorders including myeloma, lymphoma and autologous stem cell transplantation. He can converse in Hindu and looks forward to working with patients in their language.

Affiliations & Memberships

  • Australasian Leukaemia & Lymphoma Group (ALLG)
  • Medical and Scientific Advisory Group (MSAG)
  • Royal Australasian College of Physicians (RACP)
  • Royal College of Pathologist of Australasia (RCPA)
  • Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ)

Special Interests

Dr Akash Kalro accepts referrals for malignant and non-malignant blood disorders, with a special clinical interest in:
  • Clinical research
  • Lymphoma
  • Multiple myeloma
  • Stem cell transplantation

Icon Locations

Adelaide (Kurralta Park) View centre

Visiting Locations

  • Royal Adelaide Hospital
  • The Queen Elizabeth Hospital

Publications

  • Breakthrough fusariosis presenting initially with pyomyositis. A. Zhu, S. Htet, A. Kalro, & F. Szabo. Pathology, 2016; 49(1).

  • Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group: Australian Waldenström macroglobulinaemia guidelines. Talaulikar, D. C. Tam, D. Joshua, J. Ho, J. Szer H. Quach, A. Spencer, S. Harrison, P. Mollee, A. Roberts, N. Horvath, C. Lee, A. Zannettino, R. Brown, B. Augustson, W. Jaksic, J. Gibson, A. Kalff, A. Johnston, & Prince. Internal Medicine Journal, 2017. 47(1): 35-49.

  • Bisphosphonate guidelines for treatment and prevention of myeloma bone disease: Australian guidelines for bisphosphonate. O. Lee, N. Horvath, C. Lee, D. Joshua, J. Ho, J. Szer H. Quach, A. Spencer, S. Harrison, P. Mollee, A. Roberts, D. Talaulikar, R. Brown, B. Augustson, S. Ling, W. Jaksic, J. Gibson, A. Kalff, A. Johnston & A. Zannettino. Internal Medicine Journal, 2017; . 47(8): 938-951.

  • Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study. H. Quach, S. Harrison, S. Ninkovic, J. Estell, N. Horvath, N. Murphy, T. Gerber, P. Mollee, B. Durie, W. Chng. Blood, 2018; 132(Suppl_1): 1955.

  • Carfilzomib, Thalidomide and Dexamethasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study. S. Ninkovic, W. Chng, S. Harrison, N. Murphy, J. Lee, J. Estell, N. Horvath, R. Eek, B. Augustson, A. Kalro, R. Rajagopal, K. Kim, S. Bang, S. Huang, B. Butcher, B. Durie, P. Mollee & H. Quach. Clinical Lymphoma Myeloma and Leukemia, 2019; 19(10):e274-275.

View all

Search